Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID)

Documenti analoghi

• The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death
  di: Ageberg, Malin, et al.
  Pubblicazione: (2013)
• Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo
  di: Damm, Jesper Kofoed, et al.
  Pubblicazione: (2015)
• Single nucleotide variation in the TP53 3′ untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program
  di: Li, Yong, et al.
  Pubblicazione: (2013)
• MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program
  di: Xu-Monette, Zijun Y., et al.
  Pubblicazione: (2013)
• Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma
  di: Booth, Stephen, et al.
  Pubblicazione: (2020)